Cannabis OPINION: Keith Wolsko and Danielle Moore of cannabis industry recruitment specialists Simply Kind Solutions highlight the seismic recent growth of the USA’s burgeoning cannabis industry and the kinds of profiles that the industry is looking for.   We are witnessing the birth of the next great American industry. So, you…

USA As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap…

Opinion Jan Hux, the president and CEO of Diabetes Canada calls for governments to place greater importance on partnerships with patient groups for the making of big decisions in healthcare.    The establishment of a multi-stakeholder group, including patient organizations and patient representatives, could provide feedback and public policy recommendations to…

Opinion Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare disease patients and well-designed clinical trials are also essential to evaluating new therapeutics. In this article, PJ Brooks, Program Director at the Office of Rare…

Opinion On International Women’s Day 2019, David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made to close the gender investment gap, touching on key trends and biases in venture capital funding and outlining why investing in women matters.   When women business owners pitch their…

Opinion Robin Toft is the Author of WE CAN™, the Executive Woman’s Guide to Career Advancement and founder and CEO of Toft Group Executive Search, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. In this article, she discusses the…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved.    The investment in human capital is an…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

Canada Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom, Durhane explains the changing landscape for access to rare disease drugs in Canada and the actors involved in getting there.   The irony of the government processes, which, on…

Opinion Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada.    I’ve often wondered how things would be if Canada had steadily continued a path of biopharmaceutical discovery and commercialization after Banting and Best’s breakthrough in 1921, and what…

Canada As the healthcare industry continues to hype about AI’s potential to be transformative, it is important to remember that even software can harbour a certain amount of unconscious bias. Carla Smith champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT.…

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. In this article, Thompson outlines the country’s challenges to the healthcare system and the pharma…